drugset / Trial / NCT00005005

PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

NCT00005005 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

This 2-year study will test the effectiveness of combining parathyroid hormone (PTH) and alendronate for treating osteoporosis in postmenopausal women. Alendronate is a drug used to treat osteoporosis and primarily prevents bone loss, whereas PTH increases bone formation. We will treat the study participants either with PTH and alendronate, alendronate alone, or PTH alone. We will determine the effects of these treatments by looking for changes in bone mineral density in the hip and spine.

Timeline

Start
1999-10
Primary completion
2007-11
Completion
2007-11

Outcome

Missed primary endpoint

paper there was no significant difference in the increase between the parathyroid hormone group and the combination-therapy group. PMID 14500804 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 10 mg —
Subject hPTH (1-84) Unknown 100 ug Subcutaneous

Indications